ServicenavigationHauptnavigationTrailKarteikarten


Forschungsstelle
INNOSUISSE
Projektnummer
13240.1;10 PFLS-LS
Projekttitel
CAMEO- ChAracterization and optimization of selective and safe Modulators of the innate immune system for treatment of cancer and other disEases: a combined mOdelling/experimental study
Projekttitel Englisch
CAMEO- ChAracterization and optimization of selective and safe Modulators of the innate immune system for treatment of cancer and other disEases: a combined mOdelling/experimental study

Texte zu diesem Projekt

 DeutschFranzösischItalienischEnglisch
Kurzbeschreibung
-
Anzeigen
-
Anzeigen
Abstract
-
Anzeigen
-
Anzeigen

Erfasste Texte


KategorieText
Kurzbeschreibung
(Englisch)
CAMEO- ChAracterization and optimization of selective and safe Modulators of the innate immune system for treatment of cancer and other disEases: a combined mOdelling/experimental study
Kurzbeschreibung
(Französisch)
CAMEO- Characterization and optimization of selective and safe Modulators of the innate immune system for treatment of cancer and other diseases: a combined modelling/experimental study
Abstract
(Englisch)
The aim of this project is the characterization and optimization of Toll-like receptor 7 modulators¿ structure. Computational modeling, in synergy with cellular and molecular biology will provide detailed molecular information about their self-assembly properties, their interaction with the receptors and off-target problems. This knowledge will accelerate and focus the drugs optimization process leading to the GLP IND -enabling studies for entering subsequent clinical phases
Abstract
(Französisch)
The aim of this project is the characterization and optimization of Toll-like receptor 7 modulators¿ structure. Computational modeling, in synergy with cellular and molecular biology will provide detailed molecular information about their self-assembly properties, their interaction with the receptors and off-target problems. This knowledge will accelerate and focus the drugs optimization process leading to the GLP IND -enabling studies for entering subsequent clinical phases